Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old

Abstract Objectives Limited data are available concerning the extent to which the initial prostate-specific antigen (PSA) measurement in men younger than age 60 predicts for the risk of prostate cancer (CaP) and how this compares to other known risk factors. Methods From 1991 to 2001, 13,943 men younger than 60 years old participated in a CaP screening study. Men aged 40 to 49 years were eligible for the study if they had a positive family history or African-American heritage, and men older than 50 years were screened without respect to risk factors. The CaP detection rate, PSA velocity, pathologic features, …

Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old Read More »

The Swinging Pendulum of PSA Screening

Tide of opinion turning again In 2012, the U.S. Preventive Services Task Force (USPSTF) — a powerful, voluntary group that sets guidelines for primary care physicians — came out against the mass screening of healthy men with prostate-specific antigen (PSA) blood tests for the early detection of prostate cancer. That statement, which was somewhat reversed in 2018, has lived on and continues to fuel hot debates over the use of screening and whether the guidelines themselves caused more harm than benefit. And there likely will be more arguments in the years ahead as medical groups conduct uptakes on guidelines and …

The Swinging Pendulum of PSA Screening Read More »

A Re-think About PSA Testing

Benefits of PSA Test for Prostate Cancer Substantially Greater than Generally Appreciated The benefits of the prostate-specific antigen (PSA) test to screen men for prostate cancer may be greater than the harm, say investigators at Weill Cornell Medicine, NewYork-Presbyterian, University of Washington School of Medicine and the Fred Hutchinson Cancer Research Center. While organizations such as the U.S. Preventative Services Task Force (USPSTF) and the American Academy of Family Physicians have been lukewarm or opposed to the routine use of the PSA test, in a commentary published in the New England Journal of Medicine, the investigators demonstrate that these recommendations …

A Re-think About PSA Testing Read More »

New test may help detect prostate cancer earlier and with greater accuracy

A new type of test that uses complex sugars to detect prostate cancer earlier and with greater accuracy is being developed by researchers at the University of Birmingham. The test works by identifying sugars, known as glycans, in blood. These sugars are attached to protein molecules called PSA and are known to undergo distinct but subtle changes when cancer is present in the body. Read the article.

MRI and MRI-guided biopsies — a new Cochrane review

Cochrane reviews are structured, systematic, focused reviews of evidence in the field of medicine that either support or do not support specific forms of diagnosis and management of patients with or suspected of having particular disorders. A newly published Cochrane review by Drost et al. has addressed the topic of “Prostate MRI, with or without MRI‐targeted biopsy, and systematic biopsy for detecting prostate cancer“, and had just been published by the Cochrane Library.

Can Frankenstein’s finger convince men to get tested for prostate cancer? New ad campaign hopes so

Prostate Cancer Canada is encouraging men to get tested for the potentially deadly disease with a bold campaign that references historical and fictional characters in the form of latex gloves – yes, those donned by doctors for the often dreaded digital rectal exam meant to detect the presence of tumours in the male sex gland. Read the article here.

Video: “Transperineal Prostate Biopsies: a new paradigm in the diagnosis and monitoring of Prostate Cancer”

January 2018 Awareness Night Transperineal Prostate Biopsies: a new paradigm in the diagnosis and monitoring of Prostate Cancer   Dr. Stanley Flax  MB, BCh, FRCSC Staff Urologist, North York General Hospital, Co-Chair, North York General Hospital’s OR Product Standardization & Evaluation Committee, Director, Gale & Graham Wright Prostate Cancer Centre.   Dr. Adam Tunis MD, MSc, FRCPC Clinical Director of Medical Imaging Informatics, Staff Radiologist, North York General Hospital Dept. of Medical Imaging       CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 36:22 minutes 

Scroll to Top